Renaissance Technologies
CTOR

Renaissance Technologies’s Citius Oncology CTOR Stock Holding History

Renaissance Technologies’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-55,900
Closed -$113K – 3874
2025
Q3 		$113K Buy
+55,900
New +$121K ﹤0.01% 3237
2025
Q1 		– Sell
-11,196
Closed -$12.9K – 3927
2024
Q4 		$12.9K Buy
+11,196
New +$12.6K ﹤0.01% 3507

Other funds holding CTOR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies's CTOR Position: Q4 2025 in Review

Renaissance Technologies sold out of Citius Oncology (CTOR) in Q4 2025, closing a stake of 55,900 shares — an estimated $113K sold.

Renaissance Technologies first reported a position in CTOR in Q4 2024 and held it in 2 quarters. The position peaked at $113K in Q3 2025. 18 funds tracked by Wall St. Rank hold CTOR as of Q4 2025.

  • Renaissance Technologies reported no remaining Citius Oncology position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 55,900 Citius Oncology shares in Q4 2025, an estimated $113K.
  • Renaissance Technologies first reported a position in Citius Oncology in Q4 2024 and held it in 2 quarters.
  • Renaissance Technologies's Citius Oncology position peaked at $113K in Q3 2025.
  • 18 funds tracked by Wall St. Rank held Citius Oncology as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.